Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 387

1.

Nuclear Insulin-Like Growth Factor Binding Protein-3 As a Biomarker in Triple-Negative Breast Cancer Xenograft Tumors: Effect of Targeted Therapy and Comparison With Chemotherapy.

Julovi SM, Martin JL, Baxter RC.

Front Endocrinol (Lausanne). 2018 Mar 22;9:120. doi: 10.3389/fendo.2018.00120. eCollection 2018.

2.

Enhancement of mammary tumour growth by IGFBP-3 involves impaired T cell accumulation.

Scully T, Scott CD, Firth SM, Sedger LM, Pintar JE, Twigg SM, Baxter RC.

Endocr Relat Cancer. 2018 Feb;25(2):111-122. doi: 10.1530/ERC-17-0384. Epub 2017 Dec 7.

PMID:
29217518
3.

Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer.

Ochnik AM, Baxter RC.

BMC Cancer. 2017 Dec 5;17(1):820. doi: 10.1186/s12885-017-3809-0.

4.

Limitations of galactose therapy in phosphoglucomutase 1 deficiency.

Nolting K, Park JH, Tegtmeyer LC, Zühlsdorf A, Grüneberg M, Rust S, Reunert J, Du Chesne I, Debus V, Schulze-Bahr E, Baxter RC, Wada Y, Thiel C, van Schaftingen E, Fingerhut R, Marquardt T.

Mol Genet Metab Rep. 2017 Jul 31;13:33-40. doi: 10.1016/j.ymgmr.2017.07.010. eCollection 2017 Dec.

5.

Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.

Martin JL, Julovi SM, Lin MZ, de Silva HC, Boyle FM, Baxter RC.

Breast Cancer Res. 2017 Aug 4;19(1):90. doi: 10.1186/s13058-017-0882-x.

6.

Combination therapy approaches to target insulin-like growth factor receptor signaling in breast cancer.

Ochnik AM, Baxter RC.

Endocr Relat Cancer. 2016 Nov;23(11):R513-R536. Review.

7.

Insulin-like growth factor binding protein-3 links obesity and breast cancer progression.

Scully T, Firth SM, Scott CD, de Silva HC, Pintar JE, Chan-Ling T, Twigg SM, Baxter RC.

Oncotarget. 2016 Aug 23;7(34):55491-55505. doi: 10.18632/oncotarget.10675.

8.

Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.

Wong MH, Xue A, Baxter RC, Pavlakis N, Smith RC.

Neoplasia. 2016 Jul;18(7):425-35. doi: 10.1016/j.neo.2016.06.001.

9.

Silencing overexpression of FXYD3 protein in breast cancer cells amplifies effects of doxorubicin and γ-radiation on Na(+)/K(+)-ATPase and cell survival.

Liu CC, Teh R, Mozar CA, Baxter RC, Rasmussen HH.

Breast Cancer Res Treat. 2016 Jan;155(2):203-13. doi: 10.1007/s10549-015-3667-x. Epub 2016 Jan 6.

PMID:
26740212
10.

Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage.

Marzec KA, Lin MZ, Martin JL, Baxter RC.

Oncotarget. 2015 Sep 29;6(29):26583-98. doi: 10.18632/oncotarget.5612.

11.

A novel truncated form of S100P predicts disease-free survival in patients with lymph node positive breast cancer.

Chung L, Phillips L, Lin MZ, Moore K, Marsh DJ, Boyle FM, Baxter RC.

Cancer Lett. 2015 Nov 1;368(1):64-70. doi: 10.1016/j.canlet.2015.07.046. Epub 2015 Aug 11.

PMID:
26276712
12.

Targeting Insulin-Like Growth Factor Binding Protein-3 Signaling in Triple-Negative Breast Cancer.

Marzec KA, Baxter RC, Martin JL.

Biomed Res Int. 2015;2015:638526. doi: 10.1155/2015/638526. Epub 2015 Jun 28. Review.

13.

Nuclear actions of insulin-like growth factor binding protein-3.

Baxter RC.

Gene. 2015 Sep 10;569(1):7-13. doi: 10.1016/j.gene.2015.06.028. Epub 2015 Jun 12. Review.

14.

IGFBP special issue - introduction.

Baxter RC.

J Cell Commun Signal. 2015 Jun;9(2):109. doi: 10.1007/s12079-015-0295-5. Epub 2015 May 9. No abstract available.

15.

How IGF-1 activates its receptor.

Baxter RC.

J Cell Commun Signal. 2015 Mar;9(1):87. doi: 10.1007/s12079-015-0276-8. Epub 2015 Feb 26.

16.

Involvement of the insulin-like growth factor binding proteins in the cancer cell response to DNA damage.

Chua MW, Lin MZ, Martin JL, Baxter RC.

J Cell Commun Signal. 2015 Jun;9(2):167-76. doi: 10.1007/s12079-015-0262-1. Epub 2015 Jan 25.

17.

Factors that may influence the willingness of cancer patients to consent for biobanking.

Pillai U, Phillips K, Wilkins G, Baxter RC, Benn DE, Parker NR, Smith RC, Marsh DJ.

Biopreserv Biobank. 2014 Dec;12(6):409-14. doi: 10.1089/bio.2014.0039.

PMID:
25496153
18.

Involvement of insulin-like growth factor binding protein-3 in peroxisome proliferator-activated receptor gamma-mediated inhibition of breast cancer cell growth.

Pon CK, Firth SM, Baxter RC.

Mol Cell Endocrinol. 2015 Jan 5;399:354-61. doi: 10.1016/j.mce.2014.10.023. Epub 2014 Oct 31.

PMID:
25449421
19.

CCN2 requires TGF-β signalling to regulate CCAAT/enhancer binding proteins and inhibit fat cell differentiation.

Song WW, McLennan SV, Tam C, Williams PF, Baxter RC, Twigg SM.

J Cell Commun Signal. 2015 Mar;9(1):27-36. doi: 10.1007/s12079-014-0252-8. Epub 2014 Oct 30.

20.

Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer.

Chung L, Moore K, Phillips L, Boyle FM, Marsh DJ, Baxter RC.

Breast Cancer Res. 2014 Jun 16;16(3):R63. doi: 10.1186/bcr3676.

22.

Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.

Wong MH, Xue A, Julovi SM, Pavlakis N, Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC, Smith RC.

Clin Cancer Res. 2014 Aug 1;20(15):4047-58. doi: 10.1158/1078-0432.CCR-13-3377. Epub 2014 Jun 3.

23.

IGF binding proteins in cancer: mechanistic and clinical insights.

Baxter RC.

Nat Rev Cancer. 2014 May;14(5):329-41. doi: 10.1038/nrc3720. Epub 2014 Apr 10. Review.

PMID:
24722429
24.

Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.

Martin JL, de Silva HC, Lin MZ, Scott CD, Baxter RC.

Mol Cancer Ther. 2014 Feb;13(2):316-28. doi: 10.1158/1535-7163.MCT-13-0367. Epub 2013 Dec 12.

25.

TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells.

Schedlich LJ, Yenson VM, Baxter RC.

Mol Cell Endocrinol. 2013 Sep 5;377(1-2):56-64. doi: 10.1016/j.mce.2013.06.033. Epub 2013 Jul 2.

PMID:
23831640
26.

Insulin-like growth factor binding protein-3 (IGFBP-3): Novel ligands mediate unexpected functions.

Baxter RC.

J Cell Commun Signal. 2013 Aug;7(3):179-89. doi: 10.1007/s12079-013-0203-9.

27.

Tissue biomarkers of breast cancer and their association with conventional pathologic features.

Chung L, Shibli S, Moore K, Elder EE, Boyle FM, Marsh DJ, Baxter RC.

Br J Cancer. 2013 Feb 5;108(2):351-60. doi: 10.1038/bjc.2012.552. Epub 2013 Jan 8.

28.

Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays.

Chung L, Baxter RC.

Expert Rev Proteomics. 2012 Dec;9(6):599-614. doi: 10.1586/epr.12.62. Review.

PMID:
23256671
29.

The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents.

Lin MZ, Marzec KA, Martin JL, Baxter RC.

Oncogene. 2014 Jan 2;33(1):85-96. doi: 10.1038/onc.2012.538. Epub 2012 Nov 26.

PMID:
23178489
30.

Serum apolipoprotein C-II is prognostic for survival after pancreatic resection for adenocarcinoma.

Xue A, Chang JW, Chung L, Samra J, Hugh T, Gill A, Butturini G, Baxter RC, Smith RC.

Br J Cancer. 2012 Nov 20;107(11):1883-91. doi: 10.1038/bjc.2012.458.

31.

Biochemical characterization of individual human glycosylated pro-insulin-like growth factor (IGF)-II and big-IGF-II isoforms associated with cancer.

Greenall SA, Bentley JD, Pearce LA, Scoble JA, Sparrow LG, Bartone NA, Xiao X, Baxter RC, Cosgrove LJ, Adams TE.

J Biol Chem. 2013 Jan 4;288(1):59-68. doi: 10.1074/jbc.M112.432013. Epub 2012 Nov 19.

32.

Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells.

Soon PS, Kim E, Pon CK, Gill AJ, Moore K, Spillane AJ, Benn DE, Baxter RC.

Endocr Relat Cancer. 2013 Jan 7;20(1):1-12. doi: 10.1530/ERC-12-0227. Print 2013 Feb.

33.

Interaction between IGF binding protein-3 and TGFβ in the regulation of adipocyte differentiation.

de Silva HC, Firth SM, Twigg SM, Baxter RC.

Endocrinology. 2012 Oct;153(10):4799-807. Epub 2012 Aug 21.

PMID:
22910030
34.

Protection of blood retinal barrier and systemic vasculature by insulin-like growth factor binding protein-3.

Jarajapu YP, Cai J, Yan Y, Li Calzi S, Kielczewski JL, Hu P, Shaw LC, Firth SM, Chan-Ling T, Boulton ME, Baxter RC, Grant MB.

PLoS One. 2012;7(7):e39398. doi: 10.1371/journal.pone.0039398. Epub 2012 Jul 6.

35.

IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments.

Grkovic S, O'Reilly VC, Han S, Hong M, Baxter RC, Firth SM.

Oncogene. 2013 May 9;32(19):2412-20. doi: 10.1038/onc.2012.264. Epub 2012 Jul 2.

PMID:
22751133
36.

Gonadotropin signalling in epithelial ovarian cancer.

Mertens-Walker I, Baxter RC, Marsh DJ.

Cancer Lett. 2012 Nov 28;324(2):152-9. doi: 10.1016/j.canlet.2012.05.017. Epub 2012 May 22. Review.

PMID:
22634496
37.

iTRAQ-based proteomic profiling of breast cancer cell response to doxorubicin and TRAIL.

Leong S, Nunez AC, Lin MZ, Crossett B, Christopherson RI, Baxter RC.

J Proteome Res. 2012 Jul 6;11(7):3561-72. doi: 10.1021/pr2012335. Epub 2012 Jun 7.

PMID:
22587632
38.

Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS.

Xue A, Gandy RC, Chung L, Baxter RC, Smith RC.

Pancreatology. 2012 Mar-Apr;12(2):124-9. doi: 10.1016/j.pan.2012.02.009. Epub 2012 Feb 21.

PMID:
22487522
39.

Differential effects of raloxifene and estrogen on body composition in growth hormone-replaced hypopituitary women.

Birzniece V, Meinhardt UJ, Gibney J, Johannsson G, Armstrong N, Baxter RC, Ho KK.

J Clin Endocrinol Metab. 2012 Mar;97(3):1005-12. doi: 10.1210/jc.2011-2837. Epub 2011 Dec 14.

PMID:
22170716
40.

Biomarkers of breast cancer apoptosis induced by chemotherapy and TRAIL.

Leong S, McKay MJ, Christopherson RI, Baxter RC.

J Proteome Res. 2012 Feb 3;11(2):1240-50. doi: 10.1021/pr200935y. Epub 2011 Dec 14.

PMID:
22133146
41.

Insulin-like growth factor binding protein-3 inhibits migration of endometrial cancer cells.

Gribben L, Baxter RC, Marsh DJ.

Cancer Lett. 2012 Apr 1;317(1):41-8. doi: 10.1016/j.canlet.2011.11.011. Epub 2011 Nov 13.

PMID:
22085490
42.

Free insulin-like growth factor binding protein-3 (IGFBP-3) reduces retinal vascular permeability in association with a reduction of acid sphingomyelinase (ASMase).

Kielczewski JL, Li Calzi S, Shaw LC, Cai J, Qi X, Ruan Q, Wu L, Liu L, Hu P, Chan-Ling T, Mames RN, Firth S, Baxter RC, Turowski P, Busik JV, Boulton ME, Grant MB.

Invest Ophthalmol Vis Sci. 2011 Oct 21;52(11):8278-86. doi: 10.1167/iovs.11-8167.

43.

Signalling pathways of insulin-like growth factors (IGFs) and IGF binding protein-3.

Martin JL, Baxter RC.

Growth Factors. 2011 Dec;29(6):235-44. doi: 10.3109/08977194.2011.614237. Epub 2011 Sep 7. Review.

PMID:
21895551
44.

Involvement of insulin-like growth factor-binding protein-3 in the effects of histone deacetylase inhibitor MS-275 in hepatoma cells.

Lin WH, Martin JL, Marsh DJ, Jack MM, Baxter RC.

J Biol Chem. 2011 Aug 26;286(34):29540-7. doi: 10.1074/jbc.M111.263111. Epub 2011 Jul 7.

45.

D440N mutation in the acid-labile subunit of insulin-like growth factor complexes inhibits secretion and complex formation.

Firth SM, Yan X, Baxter RC.

Mol Endocrinol. 2011 Feb;25(2):307-14. doi: 10.1210/me.2010-0295. Epub 2010 Dec 22.

46.

The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor.

Bolitho C, Hahn MA, Baxter RC, Marsh DJ.

Endocr Relat Cancer. 2010 Oct 5;17(4):929-40. doi: 10.1677/ERC-10-0107. Print 2010 Dec.

47.

Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis.

Xue A, Scarlett CJ, Chung L, Butturini G, Scarpa A, Gandy R, Wilson SR, Baxter RC, Smith RC.

Br J Cancer. 2010 Jul 27;103(3):391-400. doi: 10.1038/sj.bjc.6605764. Epub 2010 Jun 29.

48.

Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}.

Mertens-Walker I, Bolitho C, Baxter RC, Marsh DJ.

Endocr Relat Cancer. 2010 Mar 8;17(2):335-49. doi: 10.1677/ERC-09-0152. Print 2010 Jun.

49.

Modulatory effect of raloxifene and estrogen on the metabolic action of growth hormone in hypopituitary women.

Birzniece V, Meinhardt U, Gibney J, Johannsson G, Baxter RC, Seibel MJ, Ho KK.

J Clin Endocrinol Metab. 2010 May;95(5):2099-106. doi: 10.1210/jc.2009-2743. Epub 2010 Mar 5.

PMID:
20207825
50.

Supplemental Content

Loading ...
Support Center